Q3 2025 Coherus Oncology Inc Earnings Call Transcript

Nov 6, 2025 / 10:00 PM GMT

Release Date Price: $1.49 (-4.79%)

Transcript 10-Q8-K

Key Points

Positve

Coherus Oncology Inc (CHRS) reported a significant improvement in their balance sheet, reducing liabilities by 69% since the end of last year.
The company achieved a 92% year-over-year increase in net revenue for their drug Loktorzi, indicating strong market performance.
Coherus Oncology Inc (CHRS) has global rights to their key pipeline products, CHS 114 and Castozaketag, allowing for potential international partnerships.
The company is actively pursuing innovative cancer treatments, with promising clinical trial progress in multiple cancer types, including nasopharyngeal, liver, and colorectal cancers.
Coherus Oncology Inc (CHRS) has demonstrated spending discipline, reducing SG&A expenses by 11% compared to last year, while increasing R&D investments by 24% to support pipeline development.

Negative

Despite strong revenue growth, the company experienced a slowdown in growth rate from 35% in Q2 to 12% in Q3, attributed to inventory accumulation in the previous quarter.
One of the four sales regions experienced flat demand due to staffing and turnover issues, impacting overall national growth.
The company faces challenges in educating community physicians about their products, as awareness remains low outside of hospital-based specialists.
Coherus Oncology Inc (CHRS) is still in the early stages of clinical trials for several key drugs, with significant data readouts not expected until 2026.
The company is navigating a competitive landscape in oncology, with the need to demonstrate clear differentiation and efficacy in their drug candidates to secure market share.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CHRS.OQ - Coherus Oncology Inc
Q3 2025 Coherus Oncology Inc Earnings Call
Nov 06, 2025 / 10:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day and thank you for standing by. Welcome to the Coherus Oncology Q3 2025 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session.

To ask a question during the session, you will need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press 11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Carrie Graham. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
---------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.